106 related articles for article (PubMed ID: 25882525)
1. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Brasca MG; Gnocchi P; Nesi M; Amboldi N; Avanzi N; Bertrand J; Bindi S; Canevari G; Casero D; Ciomei M; Colombo N; Cribioli S; Fachin G; Felder ER; Galvani A; Isacchi A; Motto I; Panzeri A; Donati D
Bioorg Med Chem; 2015 May; 23(10):2387-407. PubMed ID: 25882525
[TBL] [Abstract][Full Text] [Related]
2. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
3. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
[TBL] [Abstract][Full Text] [Related]
5. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
8. Novel 2,4-disubstituted quinazolines as cytotoxic agents and JAK2 inhibitors: Synthesis, in vitro evaluation and molecular dynamics studies.
Jyothi Buggana S; Paturi MC; Perka H; Gade DR; Vvs RP
Comput Biol Chem; 2019 Apr; 79():110-118. PubMed ID: 30785020
[TBL] [Abstract][Full Text] [Related]
9. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
Ning CQ; Lu C; Hu L; Bi YJ; Yao L; He YJ; Liu LF; Liu XY; Yu NF
Eur J Med Chem; 2015 May; 95():104-15. PubMed ID: 25800646
[TBL] [Abstract][Full Text] [Related]
12. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.
Yang SH; Khadka DB; Cho SH; Ju HK; Lee KY; Han HJ; Lee KT; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):968-77. PubMed ID: 21185195
[TBL] [Abstract][Full Text] [Related]
13.
Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
Zheng QZ; Zhang F; Cheng K; Yang Y; Chen Y; Qian Y; Zhang HJ; Li HQ; Zhou CF; An SQ; Jiao QC; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(2):880-6. PubMed ID: 20005116
[TBL] [Abstract][Full Text] [Related]
15. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
[TBL] [Abstract][Full Text] [Related]
19. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
[TBL] [Abstract][Full Text] [Related]
20. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
Purandare AV; McDevitt TM; Wan H; You D; Penhallow B; Han X; Vuppugalla R; Zhang Y; Ruepp SU; Trainor GL; Lombardo L; Pedicord D; Gottardis MM; Ross-Macdonald P; de Silva H; Hosbach J; Emanuel SL; Blat Y; Fitzpatrick E; Taylor TL; McIntyre KW; Michaud E; Mulligan C; Lee FY; Woolfson A; Lasho TL; Pardanani A; Tefferi A; Lorenzi MV
Leukemia; 2012 Feb; 26(2):280-8. PubMed ID: 22015772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
